The Emergence of DNAM-1 As the Facilitator of NK Cell-mediated Killing in Ovarian Cancer

Overview

Journal Front Immunol

Date 2025 Jan 21

PMID 39835114

Authors

Rachel Pounds

Wayne Croft

Hayden Pearce

Tasnia Hossain

Kavita Singh

Janos Balega

David N Jeevan

Sudha Sundar

Sean Kehoe

Jason Yap

Paul Moss

Jianmin Zuo

Affiliations

Soon will be listed here.

Abstract

Introduction: Ovarian cancer (OC) is the sixth most common malignancy in women and the poor 5-year survival emphasises the need for novel therapies. NK cells play an important role in the control of malignant disease but the nature of tumour-infiltrating and peripheral NK cells in OC remains unclear.

Methods: Using flow cytometric analysis, we studied the phenotype and function of NK cells in blood, primary tumour and metastatic tissue in 80 women with OC. The cell type contexture of metastatic OC tissue was explored utilising scRNAseq analysis, with a focus on portraying an immunogenic tumour microenvironment and determining the characteristics of a dysfunctional NK cell population.

Results: The proportion of peripheral NK cells was markedly elevated with a highly activated profile and increased cytotoxicity. In contrast, NK cell numbers in primary tumour and metastasis were substantially reduced, with downregulation of activatory receptors together with elevated PD-1 expression. scRNA-Seq identified 5 NK cell subpopulations along with increased exhausted and immature NK cells within tumour tissue compared to normal tissue. These features were attenuated following chemotherapy where higher levels of activated and cytotoxic NK cells associated with improved disease-free survival. Correlation of NK cell phenotype with clinical outcomes revealed high levels of DNAM-1 expression on tissue-localised and peripheral NK cells to be associated with reduced survival. Expression of PVR, the DNAM-1 ligand, was significantly increased on tumours and DNAM-1 mediated NK cell lysis of primary tumour tissue was observed .

Discussion: These findings reveal profound modulation of the tumour tissue and systemic profile of NK cells which likely contributes to the high rates of local progression and metastasis seen with OC. Immunotherapeutic approaches that overcome local immune suppression and enhance DNAM-1-targeted lysis of OC offer the potential to improve disease control.

References

Vivier E, Raulet D, Moretta A, Caligiuri M, Zitvogel L, Lanier L . Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-9. PMC: 3089969. DOI: 10.1126/science.1198687. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Hwang W, Adams S, Tahirovic E, Hagemann I, Coukos G . Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2011; 124(2):192-8. PMC: 3298445. DOI: 10.1016/j.ygyno.2011.09.039. View

Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A . CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells. J Immunol. 2014; 192(9):4184-91. DOI: 10.4049/jimmunol.1302091. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Goode E, Block M, Kalli K, Vierkant R, Chen W, Fogarty Z . Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017; 3(12):e173290. PMC: 5744673. DOI: 10.1001/jamaoncol.2017.3290. View

Cummins C, Kumar S, Long J, Balega J, Broadhead T, Duncan T . Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study. Cancers (Basel). 2022; 14(18). PMC: 9497111. DOI: 10.3390/cancers14184362. View

Olalekan S, Xie B, Back R, Eckart H, Basu A . Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. Cell Rep. 2021; 35(8):109165. DOI: 10.1016/j.celrep.2021.109165. View

Henriksen J, Nederby L, Donskov F, Waldstrom M, Adimi P, Jakobsen A . Blood natural killer cells during treatment in recurrent ovarian cancer. Acta Oncol. 2020; 59(11):1365-1373. DOI: 10.1080/0284186X.2020.1791358. View

10.

Manchanda R, Abdelraheim A, Johnson M, Rosenthal A, Benjamin E, Brunell C . Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011; 118(7):814-24. DOI: 10.1111/j.1471-0528.2011.02920.x. View

11.

Patankar M, Jing Y, Morrison J, Belisle J, Lattanzio F, Deng Y . Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol. 2005; 99(3):704-13. DOI: 10.1016/j.ygyno.2005.07.030. View

12.

Miescher S, Whiteside T, Carrel S, Von Fliedner V . Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986; 136(5):1899-907. View

13.

Henriksen J, Donskov F, Waldstrom M, Jakobsen A, Hjortkjaer M, Petersen C . Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. Acta Oncol. 2020; 59(6):652-659. DOI: 10.1080/0284186X.2019.1711173. View

14.

Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K . Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356(9244):1795-9. DOI: 10.1016/S0140-6736(00)03231-1. View

15.

James F, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton J . Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer. 2017; 17(1):657. PMC: 5607562. DOI: 10.1186/s12885-017-3585-x. View

16.

Carlsten M, Bjorkstrom N, Norell H, Bryceson Y, van Hall T, Baumann B . DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007; 67(3):1317-25. DOI: 10.1158/0008-5472.CAN-06-2264. View

17.

Kehoe S, Hook J, Nankivell M, Jayson G, Kitchener H, Lopes T . Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386(9990):249-57. DOI: 10.1016/S0140-6736(14)62223-6. View

18.

Perera Molligoda Arachchige A . Human NK cells: From development to effector functions. Innate Immun. 2021; 27(3):212-229. PMC: 8054151. DOI: 10.1177/17534259211001512. View

19.

Maas R, Hoogstad-van Evert J, Van der Meer J, Mekers V, Rezaeifard S, Korman A . TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology. 2020; 9(1):1843247. PMC: 7657585. DOI: 10.1080/2162402X.2020.1843247. View

20.

Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A . Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. Front Immunol. 2017; 8:1194. PMC: 5622151. DOI: 10.3389/fimmu.2017.01194. View